NRx Pharmaceuticals is developing NRX-101, an oral medication targeting the NMDA receptor for the treatment of suicidal bipolar depression and PTSD. This drug addresses the critical need for effective, non-addictive therapies in a landscape where no approved treatments currently exist for suicidal ideation in bipolar disorder.
Funding
$30M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Bipolar disorder affects millions, and a significant percentage of those individuals experience suicidal ideation. Currently, there are limited approved pharmaceutical options specifically for treating suicidal bipolar depression. The opioid crisis highlights the need for non-addictive alternatives for managing pain and related mental health conditions.
Solution
NRx Pharmaceuticals is developing NRX-101, an oral medication that targets the NMDA receptor, as a potential treatment for Acute and Sub-Acute Suicidal Ideation and Behavior (ASIB, SSIB) in bipolar depression and chronic pain. NRX-101 is designed to be a non-hallucinogenic, non-addictive, and non-neurotoxic approach to NMDA inhibition. The drug has received FDA Fast Track designation and Breakthrough Therapy designation, and a Special Protocol Agreement.
Target Audience
The primary target audience includes individuals with severe bipolar depression and PTSD, particularly those experiencing suicidality, as well as patients suffering from chronic pain.
Features
- Oral medication targeting the NMDA receptor
- Investigational treatment for bipolar depression with suicidal ideation
- Potential application in chronic pain management
- Non-hallucinogenic properties
- Non-addictive formulation
- Non-neurotoxic mechanism
- FDA Fast Track designation
- Breakthrough Therapy designation
- Special Protocol Agreement with the FDA